文献速递主动脉疾病

EVAS 与腹主动脉瘤修复后中期生存率的关系

Endovascular Aneurysm Sealing is Associated with Higher Medium-Term Survival than Traditional EVAR.
PubMed 文献 · Ann Vasc Surg · 2019-10-16

本研究通过倾向性加权方法,对比 Nellix EVAS 系统与 VQI 注册数据中传统 EVAR 患者的中期生存。结果显示 EVAS 组 3 年生存率高于 EVAR 组(93% vs. 88%),死亡风险降低 41%(HR 0.59 [0.38-0.92],P=0.02),尤其在动脉瘤 >5.5 cm 亚组中更显著。

要点

  • EVAS 与较高中期生存率相关,3 年生存率 93% vs. 88%。
  • EVAS 组死亡风险显著低于 EVAR 组(HR 0.59,P=0.02)。
  • 动脉瘤 >5.5 cm 患者中 EVAS 生存获益更明显(HR 0.5,P=0.02)。

核心结论

  • 在该选定患者群体中,EVAS 与高于传统 EVAR 的中期生存率相关。
  • 尽管装置问题近期出现,囊袋密封概念仍可能具有前景。

研究设计与样本

  • 倾向性加权比较研究,EVAS 组为 Nellix 美国 IDE 试验的 333 例患者,对照组为 VQI 注册中 2014-2016 年 15,431 例 EVAR 患者。
  • 应用 IDE 排除标准(血液透析、肌酐 > 2.0 mg/dL 或破裂)后,计算倾向评分并采用逆概率加权。

主要发现

  • 加权后,EVAS 组 3 年生存率 93%,对照组 88%。
  • EVAS 相比 EVAR 的死亡风险降低 41%(HR 0.59 [0.38-0.92],P=0.02)。
  • 动脉瘤 >5.5 cm 亚组中,EVAS 组 3 年生存率 92%,EVAR 组 86%(HR 0.5 [0.3-0.9],P=0.02),交互作用 P<0.001。

临床怎么用

  • 对于符合 IDE 标准的腹主动脉瘤患者,EVAS 可能提供优于传统 EVAR 的中期生存获益。
  • 动脉瘤直径 >5.5 cm 的患者可能从 EVAS 中获益更明显。

局限性

  • 为探索性分析,需进一步研究确认结果。
  • EVAS 装置近期出现的问题需考虑。
  • 未确定 EVAS 是否与较低心血管事件率相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular aneurysm repair (EVAR) is the dominant treatment modality for abdominal aortic aneurysm (AAA). Periprocedural risks are low, and cardiovascular events are the principle determinants of long-term survival. Recently, the concept of endovascular aneurysm sealing (EVAS) has been introduced into clinical investigation. In previous cohort studies, EVAS has been associated with a lower all-cause mortality than expected despite device issues. We used a propensity weighted approach to investigate whether EVAS was associated with lower all-cause mortality after aneurysm repair. METHODS: We compared 333 patients in the Nellix United States Investigational Device Exemption trial to 15,431 controls from the Vascular Quality Initiative between 2014 and 2016 after applying the exclusion criteria from the investigational device exemption (hemodialysis, creatinine > 2.0 mg/dL, or rupture). We calculated propensity scores and applied inverse probability weighting to compare risk adjusted medium-term survival using Kaplan-Meier and Cox regression. RESULTS: After weighting, patients treated with the Nellix EVAS system experienced higher 3-year survival than controls from the Vascular Quality Initiative (93% vs. 88%, respectively). This corresponded to a 41% lower risk of mortality for EVAS compared with EVAR (HR 0.59 [0.38-0.92], P = 0.02). Subgroup analysis demonstrated that the association between EVAS and higher survival was strongest in the subgroup of patients with aneurysms over 5.5 cm (P for interaction < 0.001). In this subgroup, EVAS patients experienced half the rate of mortality as those patients treated with EVAR, with 3-year survival of 92% compared with 86% (HR 0.5 [0.3-0.9], P = 0.02). CONCLUSIONS: In this select group of patients, EVAS was associated with higher medium-term survival than traditional EVAR. Although issues with the device have recently surfaced, this exploratory analysis shows that the concept of sac sealing may hold promise. Further study is needed to confirm this finding and determine whether EVAS is associated with lower rates of cardiovascular events.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. O'Donnell TFX, Carpenter JP, Lane JS, et al. Endovascular Aneurysm Sealing is Associated with Higher Medium-Term Survival than Traditional EVAR. Ann Vasc Surg. 2019. PMID: 31629124. doi:10.1016/j.avsg.2019.08.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。